Combining two types of inhibitors to fight pancreatic cancer
Co-targeting BET Bromodomain Proteins and MNK Kinases in Pancreatic Cancer
This study is looking at how a new combination of drugs can help fight pancreatic cancer by boosting the immune system and making the tumor environment healthier, which could lead to better treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11031330 on NIH RePORTER |
What this research studies
This research investigates the effects of combining BET bromodomain inhibitors with MNK kinase inhibitors to enhance anti-tumor responses in pancreatic cancer. The study aims to understand how this combination can improve the infiltration and activation of immune cells, particularly CD8+ T cells, while also normalizing the tumor environment. By targeting both cancer cells and the surrounding stroma, the research seeks to suppress the growth of pancreatic ductal adenocarcinoma (PDAC). Patients may benefit from a more effective treatment strategy that addresses both the cancer and its supportive environment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma who have not responded adequately to existing therapies.
Not a fit: Patients with other types of cancer or those who are not diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with pancreatic cancer.
How similar studies have performed: Other research has shown promising results with similar approaches targeting BET and MNK pathways, indicating potential for success in this novel combination.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Munshi, Hidayatullah G. — Northwestern University at Chicago
- Study coordinator: Munshi, Hidayatullah G.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.